Merck Sharp and Dohme reports positive lung cancer data for Keytruda

Merck Sharp and Dohme has announced new clinical trial data demonstrating the significant benefits that Keytruda can offer in the treatment of advanced lung cancer.

Findings from the pivotal phase III KEYNOTE-189 trial showed that the anti-PD-1 therapy, when used in combination with pemetrexed and cisplatin or carboplatin, was effective in the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).

Keytruda met its dual primary endpoints after demonstrating significant overall survival and progression-free survival benefits compared to pemetrexed and platinum chemotherapy alone, while the safety profile of the drug was consistent with previously-observed results.

Dr Roger Perlmutter, president of Merck Research Laboratories, said: "We are deeply grateful to the KEYNOTE-189 patients and investigators for their important contributions to this landmark study, and we look forward to presenting the data in the near future."

Merck Sharp and Dohme has the industry's largest immuno-oncology clinical research programme, with more than 650 trials studying Keytruda across a wide variety of cancers and treatment settings.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.